EA201790101A1 - Аналоги придопидина, их получение и применение - Google Patents
Аналоги придопидина, их получение и применениеInfo
- Publication number
- EA201790101A1 EA201790101A1 EA201790101A EA201790101A EA201790101A1 EA 201790101 A1 EA201790101 A1 EA 201790101A1 EA 201790101 A EA201790101 A EA 201790101A EA 201790101 A EA201790101 A EA 201790101A EA 201790101 A1 EA201790101 A1 EA 201790101A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- phenyl
- methylsulfonyl
- dopopidine
- provides
- present
- Prior art date
Links
- 238000004519 manufacturing process Methods 0.000 title abstract 2
- YGKUEOZJFIXDGI-UHFFFAOYSA-N pridopidine Chemical class C1CN(CCC)CCC1C1=CC=CC(S(C)(=O)=O)=C1 YGKUEOZJFIXDGI-UHFFFAOYSA-N 0.000 title abstract 2
- 238000000034 method Methods 0.000 abstract 3
- 150000003839 salts Chemical class 0.000 abstract 3
- 229940126534 drug product Drugs 0.000 abstract 2
- 239000012535 impurity Substances 0.000 abstract 2
- 229940126601 medicinal product Drugs 0.000 abstract 2
- 239000012907 medicinal substance Substances 0.000 abstract 2
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 2
- 238000002360 preparation method Methods 0.000 abstract 2
- FNBCNCDBZZLEGS-GJZGRUSLSA-N (3R,4S)-4-(3-methylsulfonylphenyl)-1-propylpiperidin-3-ol Chemical compound CS(=O)(=O)C=1C=C(C=CC=1)[C@H]1[C@H](CN(CC1)CCC)O FNBCNCDBZZLEGS-GJZGRUSLSA-N 0.000 abstract 1
- QPFAIUUVQRVVLX-UHFFFAOYSA-N 1-(2-methylpentyl)-4-(3-methylsulfonylphenyl)piperidine Chemical compound CC(CN1CCC(CC1)C1=CC(=CC=C1)S(=O)(=O)C)CCC QPFAIUUVQRVVLX-UHFFFAOYSA-N 0.000 abstract 1
- KKYKIAGDGJLHIP-UHFFFAOYSA-N 1-[3,3-bis(3-methylsulfonylphenyl)propyl]-4-(3-methylsulfonylphenyl)piperidin-2-one Chemical compound CS(=O)(=O)C=1C=C(C=CC=1)C(CCN1C(CC(CC1)C1=CC(=CC=C1)S(=O)(=O)C)=O)C1=CC(=CC=C1)S(=O)(=O)C KKYKIAGDGJLHIP-UHFFFAOYSA-N 0.000 abstract 1
- QMSRDMJFXAPSDL-UHFFFAOYSA-N 1-propyl-4-[3-[4-[3-(1-propylpiperidin-4-yl)phenyl]sulfonylbutylsulfonyl]phenyl]piperidine Chemical compound C(CC)N1CCC(CC1)C=1C=C(C=CC=1)S(=O)(=O)CCCCS(=O)(=O)C1=CC(=CC=C1)C1CCN(CC1)CCC QMSRDMJFXAPSDL-UHFFFAOYSA-N 0.000 abstract 1
- XBHZHZSADHKDIQ-UHFFFAOYSA-N 4-(3-methylsulfinylphenyl)-1-propyl-3,6-dihydro-2h-pyridine Chemical compound C1N(CCC)CCC(C=2C=C(C=CC=2)S(C)=O)=C1 XBHZHZSADHKDIQ-UHFFFAOYSA-N 0.000 abstract 1
- YDZAGNOUGPIQDK-UHFFFAOYSA-N 4-(3-methylsulfonylphenyl)-1-propyl-3,6-dihydro-2h-pyridine Chemical compound C1N(CCC)CCC(C=2C=C(C=CC=2)S(C)(=O)=O)=C1 YDZAGNOUGPIQDK-UHFFFAOYSA-N 0.000 abstract 1
- ZDXQESGEKBKRGR-UHFFFAOYSA-N 4-(3-methylsulfonylphenyl)-1-propylpiperidin-4-ol Chemical compound C1CN(CCC)CCC1(O)C1=CC=CC(S(C)(=O)=O)=C1 ZDXQESGEKBKRGR-UHFFFAOYSA-N 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
- C07D211/24—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by sulfur atoms to which a second hetero atom is attached
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/40—Oxygen atoms
- C07D211/42—Oxygen atoms attached in position 3 or 5
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/40—Oxygen atoms
- C07D211/44—Oxygen atoms attached in position 4
- C07D211/52—Oxygen atoms attached in position 4 having an aryl radical as the second substituent in position 4
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/88—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/88—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86
- G01N2030/8809—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample
- G01N2030/8872—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample impurities
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physics & Mathematics (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Medicinal Preparation (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Spectroscopy & Molecular Physics (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462019337P | 2014-06-30 | 2014-06-30 | |
| US201462076436P | 2014-11-06 | 2014-11-06 | |
| PCT/US2015/038349 WO2016003919A1 (en) | 2014-06-30 | 2015-06-29 | Analogs of pridopidine, their preparation and use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EA201790101A1 true EA201790101A1 (ru) | 2017-06-30 |
Family
ID=54929343
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201790101A EA201790101A1 (ru) | 2014-06-30 | 2015-06-29 | Аналоги придопидина, их получение и применение |
Country Status (17)
| Country | Link |
|---|---|
| US (4) | US10130621B2 (enExample) |
| EP (2) | EP3160470B1 (enExample) |
| JP (2) | JP6800842B2 (enExample) |
| CN (2) | CN106456618A (enExample) |
| AU (1) | AU2015284385B2 (enExample) |
| BR (1) | BR112016030968B1 (enExample) |
| CA (1) | CA2951494C (enExample) |
| DK (1) | DK3160470T3 (enExample) |
| EA (1) | EA201790101A1 (enExample) |
| ES (1) | ES2927888T3 (enExample) |
| HU (1) | HUE060242T2 (enExample) |
| IL (2) | IL249601B (enExample) |
| MX (1) | MX382649B (enExample) |
| PL (1) | PL3160470T3 (enExample) |
| TW (1) | TW201613859A (enExample) |
| UY (1) | UY36192A (enExample) |
| WO (1) | WO2016003919A1 (enExample) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| USRE46117E1 (en) | 1999-12-22 | 2016-08-23 | Teva Pharmaceuticals International Gmbh | Modulators of dopamine neurotransmission |
| JP2013536825A (ja) | 2010-09-03 | 2013-09-26 | イバックス・インターナショナル・ゲーエムベーハー | ドパミン作動性安定化剤として有用なプリドピジンの重水素化類似体 |
| TWI579272B (zh) | 2011-12-08 | 2017-04-21 | 梯瓦製藥國際有限責任公司 | 普多比啶（ｐｒｉｄｏｐｉｄｉｎｅ）之氫溴酸鹽 |
| US11090297B2 (en) * | 2013-06-21 | 2021-08-17 | Prilenia Neurotherapeutics Ltd. | Pridopidine for treating huntington's disease |
| HK1221646A1 (zh) | 2013-06-21 | 2017-06-09 | Teva Pharmaceuticals International Gmbh | 高剂量普利多匹定用於治疗亨廷顿舞蹈症的用途 |
| TW201613859A (en) | 2014-06-30 | 2016-04-16 | Teva Pharma | Analogs of PRIDOPIDINE, their preparation and use |
| MX2017008136A (es) | 2014-12-22 | 2018-03-06 | Teva Pharmaceuticals Int Gmbh | Sal de l-tartrato de pridopidina. |
| US11471449B2 (en) | 2015-02-25 | 2022-10-18 | Prilenia Neurotherapeutics Ltd. | Use of pridopidine to improve cognitive function and for treating Alzheimer's disease |
| JP6887952B2 (ja) | 2015-02-25 | 2021-06-16 | プリレニア ニューロセラピューティクス リミテッド | 認知機能を改善するため、およびアルツハイマー病を治療するためのプリドピジンの使用 |
| AR105434A1 (es) | 2015-07-22 | 2017-10-04 | Teva Pharmaceuticals Int Gmbh | Proceso para preparar pridopidina |
| JP7034488B2 (ja) | 2016-02-24 | 2022-03-14 | プリレニア・ニューロセラピューティクス・エルティーディー | プリドピジンを使用する神経変性眼疾患の治療 |
| CA3035099C (en) | 2016-08-24 | 2023-01-17 | Prilenia Therapeutics Development Ltd. | Use of pridopidine for treating dystonias |
| EP4516356A3 (en) | 2016-08-24 | 2025-05-14 | Prilenia Neurotherapeutics Ltd. | Use of pridopidine for treating functional decline |
| US12102627B2 (en) | 2016-09-16 | 2024-10-01 | Prilenia Neurotherapeutics Ltd. | Use of pridopidine for treating rett syndrome |
| CA3050700C (en) | 2017-01-20 | 2023-10-03 | Prilenia Neurotherapeutics Ltd. | Use of pridopidine for the treatment of fragile x syndrome |
| SI4154882T1 (sl) | 2017-08-14 | 2026-01-30 | Prilenia Neurotherapeutics Ltd. | Zdravljenje amiotrofične lateralne skleroze s pridopidinom |
| CA3073568A1 (en) | 2017-08-30 | 2019-03-07 | Prilenia Neurotherapeutics Ltd. | High concentration dosage forms of pridopidine |
| US12036213B2 (en) | 2017-09-08 | 2024-07-16 | Prilenia Neurotherapeutics Ltd. | Pridopidine for treating drug induced dyskinesias |
| JP2020533296A (ja) | 2017-09-08 | 2020-11-19 | プリレニア ニューロセラピューティクス リミテッド | 薬物誘発性ジスキネジアを治療するためのプリドピジン |
| CN113395964A (zh) | 2019-02-04 | 2021-09-14 | 普瑞尼亚神经治疗有限公司 | 用于帕金森氏病和与帕金森症相关的其它疾病的低剂量普利多匹定 |
| AU2020243692B2 (en) * | 2019-03-15 | 2023-03-02 | Prilenia Neurotherapeutics Ltd. | Treatment of mitochondrial associated diseases and disorders, including symptoms thereof using pridopidine |
| CN121243170A (zh) | 2019-06-12 | 2026-01-02 | 普瑞尼亚神经治疗有限公司 | 用于治疗亨廷顿病及其症状的包含普利多匹定及其类似物的组合物 |
| CA3176917A1 (en) * | 2020-05-04 | 2021-11-11 | Prilenia Neurotherapeutics Ltd. | Treatment of viral infection, disease or disorder using a selective s1r agonist |
| MX2023004516A (es) * | 2020-10-20 | 2023-05-04 | Prilenia Neurotherapeutics Ltd | Uso de pridopidina y analogos para el tratamiento de la ansiedad y la depresion. |
| CN116472043A (zh) * | 2020-10-20 | 2023-07-21 | 普瑞尼亚神经治疗有限公司 | 普利多匹定和类似物用于治疗焦虑和抑郁的用途 |
| IL307462A (en) * | 2021-04-14 | 2023-12-01 | Prilenia Neurotherapeutics Ltd | Treatment of prodromal huntington disease |
| JP7829678B2 (ja) * | 2021-10-11 | 2026-03-13 | プリレニア ニューロセラピューティクス リミテッド | 神経変性眼疾患を治療するためのプリドピジン及びその類似体 |
| CN114716391B (zh) * | 2022-04-24 | 2023-12-12 | 杭州仟源保灵药业有限公司 | 一种醋甲唑胺杂质及其制备方法和应用 |
| EP4519246A4 (en) * | 2022-05-03 | 2025-08-13 | Prilenia Neurotherapeutics Ltd | PROCESSES AND INTERMEDIATES FOR THE PREPARATION OF PRIDOPIDINE |
| CN118924710A (zh) * | 2024-08-05 | 2024-11-12 | 四川大学 | 细辛脑在制备治疗和/或预防眼部疾病药物中的应用和一种组合物及其应用 |
| WO2026035949A1 (en) * | 2024-08-08 | 2026-02-12 | Prilenia Therapeutics Inc. | Combination of pridopidine and low dose anti-dopaminergic medication (adm) for treating huntington disease and sympto thereof |
| WO2026080658A1 (en) | 2024-10-10 | 2026-04-16 | Prilenia Therapeutics Inc. | Pridopidine for the treatment of distal hereditary motor neuropathy (dhmn) |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6472736A (en) | 1987-09-14 | 1989-03-17 | Toshiba Corp | Mri apparatus |
| USRE46117E1 (en) | 1999-12-22 | 2016-08-23 | Teva Pharmaceuticals International Gmbh | Modulators of dopamine neurotransmission |
| SE9904724D0 (sv) * | 1999-12-22 | 1999-12-22 | Carlsson A Research Ab | New modulators of dopamine neurotransmission I |
| JP2007522130A (ja) * | 2004-01-21 | 2007-08-09 | テバ ファーマシューティカル インダストリーズ リミティド | 塩酸バラシクロビルの調製方法 |
| ATE449071T1 (de) * | 2004-06-08 | 2009-12-15 | Nsab Af Neurosearch Sweden Ab | Neue substituierte piperidine als modulatoren der dopamin neurotransmission |
| SE0401465D0 (sv) | 2004-06-08 | 2004-06-08 | Carlsson A Research Ab | New substituted piperdines as modulators of dopamine neurotransmission |
| CA2578750A1 (en) * | 2004-09-04 | 2006-03-16 | Teva Pharmaceutical Industries, Ltd. | A valacyclovir impurity, process for the preparation of valacyclovir impurity and use as a reference standard |
| EP1807394A1 (en) * | 2004-10-13 | 2007-07-18 | Neurosearch Sweden AB | Process for the synthesis of 4-(3-sulfonylphenyl)-piperidines |
| CA2584831C (en) * | 2004-10-13 | 2013-09-17 | Neurosearch Sweden Ab | Process for the synthesis of 4-(3-methanesulfonylphenyl)-1-n-propyl-piperidine |
| EP1716139A1 (en) * | 2005-01-03 | 2006-11-02 | Teva Pharmaceutical Industries Ltd. | Olmesartan medoxomil with reduced levels of impurities |
| SE529246C2 (sv) * | 2005-10-13 | 2007-06-12 | Neurosearch Sweden Ab | Nya disubstituerade fenyl-piperidiner som modulatorer för dopaminneurotransmission |
| EP1961742A1 (en) | 2007-02-22 | 2008-08-27 | Novartis AG | compounds of formula (I) as serine protease inhibitors |
| CN101711236B (zh) | 2007-04-12 | 2012-10-31 | Nsab神经研究瑞典公司分公司 | 表现出改善的心血管副作用特性的多巴胺受体稳定剂/调节剂的n-氧化物和/或二-n-氧化物衍生物 |
| WO2008155357A2 (en) * | 2007-06-18 | 2008-12-24 | A. Carlsson Research Ab | Use of dopamine stabilizers |
| US20110206782A1 (en) * | 2010-02-24 | 2011-08-25 | Auspex Pharmaceuticals, Inc. | Piperidine modulators of dopamine receptor |
| JP2013532233A (ja) | 2010-07-02 | 2013-08-15 | アクティエボラゲット・エスコーエッフ | 機械構成要素、および表面硬化方法 |
| JP2013536825A (ja) | 2010-09-03 | 2013-09-26 | イバックス・インターナショナル・ゲーエムベーハー | ドパミン作動性安定化剤として有用なプリドピジンの重水素化類似体 |
| BR112014005389A8 (pt) | 2011-09-07 | 2018-04-03 | Ivax Int Gmbh | Sal cloridrato de 4- (3-metanossulfonil-fenil) -1- propil-piperidina em uma forma cristalina, composição farmacêutica compreendendo o mesmo e usos do dito sal |
| TWI579272B (zh) | 2011-12-08 | 2017-04-21 | 梯瓦製藥國際有限責任公司 | 普多比啶（ｐｒｉｄｏｐｉｄｉｎｅ）之氫溴酸鹽 |
| AU2013243461A1 (en) | 2012-04-04 | 2014-11-06 | Teva Pharmaceuticals International Gmbh | Pharmaceutical compositions for combination therapy |
| MX2015003608A (es) | 2012-09-27 | 2015-06-05 | Teva Pharma | Combinacion de laquinimod y pridopidina para tratar trastornos neurodegenerativos. |
| US20150216850A1 (en) | 2012-09-27 | 2015-08-06 | Michael Hayden | Combination of rasagiline and pridopidine for treating neurodegenerative disorders, in particular huntington's disease |
| HK1221646A1 (zh) | 2013-06-21 | 2017-06-09 | Teva Pharmaceuticals International Gmbh | 高剂量普利多匹定用於治疗亨廷顿舞蹈症的用途 |
| MX377576B (es) | 2014-01-22 | 2025-03-04 | Prilenia Neurotherapeutics Ltd | Formulaciones de pridopidina de liberación modificada. |
| TW201613859A (en) | 2014-06-30 | 2016-04-16 | Teva Pharma | Analogs of PRIDOPIDINE, their preparation and use |
| MX2017008136A (es) | 2014-12-22 | 2018-03-06 | Teva Pharmaceuticals Int Gmbh | Sal de l-tartrato de pridopidina. |
| WO2016138135A1 (en) | 2015-02-25 | 2016-09-01 | Teva Pharmaceuticals International Gmbh | Sigma-1 receptor modulators for treating huntington's disease |
| JP6887952B2 (ja) | 2015-02-25 | 2021-06-16 | プリレニア ニューロセラピューティクス リミテッド | 認知機能を改善するため、およびアルツハイマー病を治療するためのプリドピジンの使用 |
| AR105434A1 (es) | 2015-07-22 | 2017-10-04 | Teva Pharmaceuticals Int Gmbh | Proceso para preparar pridopidina |
| EP3324967A4 (en) | 2015-07-22 | 2019-03-20 | Prilenia Therapeutics Development Ltd. | PRIDOPIDINE-BASED FORMULATIONS AND USE OF THE SAME |
| EP4516356A3 (en) * | 2016-08-24 | 2025-05-14 | Prilenia Neurotherapeutics Ltd. | Use of pridopidine for treating functional decline |
-
2015
- 2015-06-23 TW TW104120197A patent/TW201613859A/zh unknown
- 2015-06-26 UY UY0001036192A patent/UY36192A/es not_active Application Discontinuation
- 2015-06-29 JP JP2017520772A patent/JP6800842B2/ja active Active
- 2015-06-29 CN CN201580035520.9A patent/CN106456618A/zh active Pending
- 2015-06-29 EP EP15814023.6A patent/EP3160470B1/en active Active
- 2015-06-29 MX MX2016017332A patent/MX382649B/es unknown
- 2015-06-29 WO PCT/US2015/038349 patent/WO2016003919A1/en not_active Ceased
- 2015-06-29 PL PL15814023.6T patent/PL3160470T3/pl unknown
- 2015-06-29 BR BR112016030968-5A patent/BR112016030968B1/pt active IP Right Grant
- 2015-06-29 EA EA201790101A patent/EA201790101A1/ru unknown
- 2015-06-29 EP EP22165235.7A patent/EP4049998A1/en active Pending
- 2015-06-29 AU AU2015284385A patent/AU2015284385B2/en active Active
- 2015-06-29 HU HUE15814023A patent/HUE060242T2/hu unknown
- 2015-06-29 CN CN202110715595.9A patent/CN113511997A/zh active Pending
- 2015-06-29 US US14/754,339 patent/US10130621B2/en active Active
- 2015-06-29 CA CA2951494A patent/CA2951494C/en active Active
- 2015-06-29 DK DK15814023.6T patent/DK3160470T3/da active
- 2015-06-29 ES ES15814023T patent/ES2927888T3/es active Active
-
2016
- 2016-12-15 IL IL249601A patent/IL249601B/en active IP Right Grant
-
2018
- 2018-10-03 US US16/150,977 patent/US10406145B2/en active Active
-
2019
- 2019-08-08 US US16/535,107 patent/US11141412B2/en active Active
-
2020
- 2020-01-28 IL IL272306A patent/IL272306B/en active IP Right Grant
- 2020-04-24 JP JP2020077160A patent/JP7035108B2/ja active Active
-
2021
- 2021-10-11 US US17/498,075 patent/US20220023280A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA201790101A1 (ru) | Аналоги придопидина, их получение и применение | |
| CY1125613T1 (el) | 4-ιμιδαζοπυριδαζιν-1-υλ-βενζαμιδια και 4- ιμιδαζοτριαζιν-1-υλ-βενζαμιδια ως αναστολεις βτκ | |
| PH12019500188A1 (en) | Piperidine cxcr7 receptor modulators | |
| PH12018500259A1 (en) | Muscarinic agonists | |
| JO3430B1 (ar) | مشتقات حمض أميني جديدة، عملية لتحضيرها وتركيبات صيدلية تحتوي عليها | |
| PH12017500281A1 (en) | Pyrrolopyrimidine compounds used as tlr7 agonist | |
| EA201691242A1 (ru) | Фармацевтические композиции, содержащие azd9291 | |
| BR112015000229A2 (pt) | formulações aquosas estáveis de etanercept | |
| MX393820B (es) | Derivado de ?-aminoácido tricíclico fusionado, método de preparación, y uso médico del mismo. | |
| EA201691674A1 (ru) | 1,2-замещенные циклопентаны в качестве антагонистов рецептора орексина | |
| MX394588B (es) | Composición farmacéutica. | |
| CY1122077T1 (el) | Νεα δακτυλιωμενα φαινοξυακεταμιδια | |
| EA202191114A1 (ru) | Производные пиридинилсульфонамида, фармацевтические композиции и их применение | |
| EA201890532A1 (ru) | Новые аннелированные бензамиды | |
| TR201819805T4 (tr) | Flavaglin türevleri̇. | |
| MX385518B (es) | FORMULACIÓN QUE TIENE CARACTERÍSTICAS MEJORADAS DE LIBERACIÓN DE FÁRMACOS pH DEPENDIENTES, QUE CONTIENEN ESOMEPRAZOL O UNA DE SUS SALES FARMACÉUTICAS ACEPTABLE. | |
| WO2016209978A3 (en) | Thiol-ene based peptide stapling and uses thereof | |
| WO2018005801A3 (en) | Novel non-systemic tgr5 agonists | |
| EA201891682A1 (ru) | Производное азациклического амида, способ его получения и фармацевтическое применение | |
| UA117154C2 (uk) | Антагоністи s1p3 | |
| EA201792237A1 (ru) | Фармацевтические составы | |
| MX378947B (es) | Composición farmacéutica estable para administración oral. | |
| EA201591150A1 (ru) | Твердая единая форма с высоким содержанием фексофенадина и способ ее получения | |
| EA201991286A1 (ru) | Твердая фармацевтическая композиция для перорального применения, содержащая тенофовир и эмтрицитабин | |
| MX2017012022A (es) | Compuestos organicos. |